Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials

Overview

Journal Front Neurol

Specialty Neurology

Date 2017 Oct 11

PMID 28993751

Citations 22

Authors

Syed I Khalid

Leonel Ampie

Ryan Kelly

Shafeeq S Ladha

Christopher Dardis

Affiliations

Soon will be listed here.

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of motor neurons. Though many molecular and genetic causes are thought to serve as predisposing or disease propagating factors, the underlying pathogenesis of the disease is not known. Recent discoveries have demonstrated the presence of inflammation propagating substrates in the central nervous system of patients afflicted with ALS. Over the past decade, this hypothesis has incited an effort to better understand the role of the immune system in ALS and has led to the trial of several potential immune-modulating therapies. Here, we briefly review advances in the role of such therapies. The clinical trials discussed here are currently ongoing or have been concluded at the time of writing.

Citing Articles

Exploring clinical chemistry markers in amyotrophic lateral sclerosis: insights into survival and disease trajectories.

Psychogios I, Hu Y, Seitz C, Joyce E, Lovik A, Ingre C J Neurol. 2024; 272(1):7.

PMID: 39666115 PMC: 11638388. DOI: 10.1007/s00415-024-12774-7.

Aberrant protein aggregation in amyotrophic lateral sclerosis.

Wang H, Zeng R J Neurol. 2024; 271(8):4826-4851.

PMID: 38869826 DOI: 10.1007/s00415-024-12485-z.

Targeting brain-peripheral immune responses for secondary brain injury after ischemic and hemorrhagic stroke.

Duan M, Xu Y, Li Y, Feng H, Chen Y J Neuroinflammation. 2024; 21(1):102.

PMID: 38637850 PMC: 11025216. DOI: 10.1186/s12974-024-03101-y.

T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression.

Yazdani S, Seitz C, Cui C, Lovik A, Pan L, Piehl F Nat Commun. 2022; 13(1):6733.

PMID: 36347843 PMC: 9643478. DOI: 10.1038/s41467-022-34526-9.

A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis.

Lunetta C, Lizio A, Cabona C, Gerardi F, Sansone V, Corbo M J Neurol. 2022; 269(10):5337-5346.

PMID: 35596795 DOI: 10.1007/s00415-022-11185-w.

References

Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G . Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010; 9(11):883-97. DOI: 10.1038/nrd3248. View

Lull M, Block M . Microglial activation and chronic neurodegeneration. Neurotherapeutics. 2010; 7(4):354-65. PMC: 2951017. DOI: 10.1016/j.nurt.2010.05.014. View

Radford R, Morsch M, Rayner S, Cole N, Pountney D, Chung R . The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia. Front Cell Neurosci. 2015; 9:414. PMC: 4621294. DOI: 10.3389/fncel.2015.00414. View

Garlanda C, Dinarello C, Mantovani A . The interleukin-1 family: back to the future. Immunity. 2013; 39(6):1003-18. PMC: 3933951. DOI: 10.1016/j.immuni.2013.11.010. View

Choi S, Yu E, Kim D, Sugimori M, Llinas R . RNS60, a charge-stabilized nanostructure saline alters Xenopus Laevis oocyte biophysical membrane properties by enhancing mitochondrial ATP production. Physiol Rep. 2015; 3(3). PMC: 4393147. DOI: 10.14814/phy2.12261. View

McGrath M, Kahn J, Herndier B . Development of WF10, a novel macrophage-regulating agent. Curr Opin Investig Drugs. 2002; 3(3):365-73. View

Rentzos M, Evangelopoulos E, Sereti E, Zouvelou V, Marmara S, Alexakis T . Alterations of T cell subsets in ALS: a systemic immune activation?. Acta Neurol Scand. 2011; 125(4):260-4. DOI: 10.1111/j.1600-0404.2011.01528.x. View

Cherry J, Olschowka J, OBanion M . Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014; 11:98. PMC: 4060849. DOI: 10.1186/1742-2094-11-98. View

Stadelmann C, Wegner C, Bruck W . Inflammation, demyelination, and degeneration - recent insights from MS pathology. Biochim Biophys Acta. 2010; 1812(2):275-82. DOI: 10.1016/j.bbadis.2010.07.007. View

10.

Bougea A, Anagnostou E, Stamboulis E, Kararizou E . Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis. Rev Neurol (Paris). 2014; 170(3):228-9. DOI: 10.1016/j.neurol.2013.11.004. View

11.

Keep M, Elmer E, Fong K, Csiszar K . Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res. 2001; 894(2):327-31. DOI: 10.1016/s0006-8993(01)02012-1. View

12.

ORourke J, Bogdanik L, Yanez A, Lall D, Wolf A, Muhammad A . C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016; 351(6279):1324-9. PMC: 5120541. DOI: 10.1126/science.aaf1064. View

13.

Maier A, Deigendesch N, Muller K, Weishaupt J, Krannich A, Rohle R . Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis--A Pilot Study. PLoS One. 2015; 10(10):e0139684. PMC: 4596620. DOI: 10.1371/journal.pone.0139684. View

14.

Trias E, Ibarburu S, Barreto-Nunez R, Babdor J, Maciel T, Guillo M . Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J Neuroinflammation. 2016; 13(1):177. PMC: 4940876. DOI: 10.1186/s12974-016-0620-9. View

15.

Pollari E, Savchenko E, Jaronen M, Kanninen K, Malm T, Wojciechowski S . Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2011; 8:74. PMC: 3146845. DOI: 10.1186/1742-2094-8-74. View

16.

Feng J, Misu T, Fujihara K, Sakoda S, Nakatsuji Y, Fukaura H . Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler. 2004; 10(5):494-8. DOI: 10.1191/1352458504ms1070oa. View

17.

Trojsi F, Sagnelli A, Cirillo G, Piccirillo G, Femiano C, Izzo F . Amyotrophic lateral sclerosis and multiple sclerosis overlap: a case report. Case Rep Med. 2013; 2012:324685. PMC: 3541770. DOI: 10.1155/2012/324685. View

18.

David S, Fry E, Lopez-Vales R . Novel roles for Nogo receptor in inflammation and disease. Trends Neurosci. 2008; 31(5):221-6. DOI: 10.1016/j.tins.2008.02.002. View

19.

Taylor J, Brown Jr R, Cleveland D . Decoding ALS: from genes to mechanism. Nature. 2016; 539(7628):197-206. PMC: 5585017. DOI: 10.1038/nature20413. View

20.

Serraino D, Piselli P, Busnach G, Burra P, Citterio F, Arbustini E . Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer. 2007; 43(14):2117-23. DOI: 10.1016/j.ejca.2007.07.015. View